课题基金 / 基金详情

Cardioprotection against Adverse Side-Effects of Ibrutinib in Cancer Chemotherapy

Cardioprotection against Adverse Side-Effects of Ibrutinib in Cancer Chemotherapy
癌症化疗中依鲁替尼不良副作用的心脏保护作用
批准号:
487140
负责人:
Nanthakumar Kumaraswamy
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2023
资助国家:
加拿大
项目状态:
已结题
起止时间:
2023-04-01 至 2024-04-01

项目摘要

项目成果

Nanthakumar Kumaraswamy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ibrutinib is a common treatment in chemotherapy for blood cancer. While this drug is effective against cancer, many patients suffer from toxic side-effects, such as irregular heartbeats, which can be life-threatening. We have therefore started work to det
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Ventricular Tachycardia: Challenges in the Intramural Myocardium
  • 批准号:
    463242
  • 项目类别:
    Operating Grants
  • 资助金额:
    $36.11万
  • 财政年份:
    2022
  • 负责人:
    Nanthakumar Kumaraswamy
  • 依托单位:
Augmented Renal Denervation for the Prevention of Cardiac Arrhythmias.
  • 批准号:
    358240
  • 项目类别:
    Operating Grants
  • 资助金额:
    $43.75万
  • 财政年份:
    2016
  • 负责人:
    Nanthakumar Kumaraswamy
  • 依托单位:
Translational Studies of RyR2 Modulation for Human Ventricular Fibrillation
  • 批准号:
    323762
  • 项目类别:
    Operating Grants
  • 资助金额:
    $45.59万
  • 财政年份:
    2015
  • 负责人:
    Nanthakumar Kumaraswamy
  • 依托单位:
Mitochondrial Redox State Modulation to Improve Human Cardiac Arrest Outcome.
  • 批准号:
    282148
  • 项目类别:
    Operating Grants
  • 资助金额:
    $19.92万
  • 财政年份:
    2013
  • 负责人:
    Nanthakumar Kumaraswamy
  • 依托单位:
海外基金